Rapid Response, Low-Cost Vaccine Manufacturing

Rapid Response, Low-Cost Vaccine Manufacturing

Rapid Response, Low-Cost Vaccine Manufacturing

Welcome to the replay of our webinar hosted by Batavia Biosciences in partnership with DCVMN. This informative session, titled “Rapid Response, Low-Cost Manufacturing of Viral Vaccines Against Emerging Infectious Disease Threats,” addressed some of the most pressing issues in today’s global health landscape.

Dealing with Emerging Threats Infectious Disease

In a world where vaccine inequality and public hesitancy continue to plague our efforts to increase coverage, it is essential to adapt and innovate. Did you know that approximately 25 million children under the age of one did not receive essential vaccines, marking the highest count since 2009? During the COVID-19 pandemic, global vaccine coverage fell to 81%, with a mere 29% of the population in developing countries receiving vaccinations against Covid.

The challenges we face may seem overwhelming, but through the advancements in our HIP-Vax platform, we believe we’re poised to make a significant difference. The HIP-Vax platform aims to shorten the time it takes to bring vaccines to the clinic, dramatically reducing manufacturing costs.

Our speaker for the session was Alfred Luitjens, the Global Technical Sales Director at Batavia Biosciences. Alfred is well-versed in the complexities of vaccine production and eager to share insights into how we can work towards a more equitable future through innovative solutions.


The Developing Countries Vaccine Manufacturers Network (DCVMN) is a voluntary alliance of over 40 vaccine manufacturers from 15 developing countries, firmly engaged in innovation, research, development, manufacturing, and supply of high-quality vaccines to 170 countries striving to enable equitable access to vaccines.

DCVMN aims to protect people against known and emerging infectious diseases globally by increasing the production of high-quality vaccines in developing countries. It works to strengthen vaccine manufacturers through the provision of advocacy, professional training programs on technological and production improvements, and acting as a liaison to foster partnerships and funding. DCVMN also encourages technology transfer initiatives and educates the public about the availability of safe, effective and affordable vaccines for all people.

Read more on their website.


Webinar: Tech Transfer For Viral Vectors

Webinar: Tech Transfer For Viral Vectors

Webinar: Tech Transfer For Viral Vectors

Batavia Biosciences - Favicon

When? May 16th, 16.00 CET

This webinar delves into the exciting world of Tech Transfer and how it can help bring cutting-edge scientific research from academia to the clinic, where it can impact people’s lives.

Whether you’re a researcher, a biotech entrepreneur, or a viral vector enthusiast, this webinar is not to be missed. You will have the opportunity to learn from the best, ask questions, and access our resources. 

So, register now and be a part of this exciting session to help navigate the road from academia to the clinic.

Key learnings:

  • Tech Transfer in an ideal world
  • Commonly encountered challenges
  • How you can prepare for a smooth transition.
  • Showcase materials and best practices from the field
Monika Ballmann, Ph.D.

Monika Ballmann, Ph.D.

Dr Ballmann is the Associate Director of the Viral Vector and Vaccine Development Department at Batavia Biosciences. She is responsible for viral vaccine and viral vector development programs, small-scale process development studies, and the production of pre-GMP grade viral vaccine and vector batches.

During the past 12 years, she held diverse positions in virology and process development at Batavia Biosciences and the Hungarian Academy of Sciences. In addition, she has worked in several international consortia, including both for-profit and non-profit programs. She was involved in the development and production of several products, among many others, adenovirus-, measles-, and arenavirus-based viral vectors, poliovirus, SARS-CoV-2 and measles vaccines.

Dr Ballmann holds a PhD in veterinary virology and is (co-)author of 13 scientific publications.

Low-cost viral vector manufacturing

High-throughput screening for viral vectors

Viral vector manufacturing

Maximizing protein expression